Dear Editor, Myelodysplastic syndrome with isolated del (5q) and JAK2 V617F mutation is a distinct entity within the World Health Organization (WHO) category myelodysplastic syndromes (MDS) [1] . JAK2 V617F is a gain of function mutation, typically associated with myeloproliferative neoplasms (MPN) [2] . However, approximately 5 % of patients with isolated del (5q) also harbours the JAK2 V617F mutation [3, 4] . No correlation was found between isolated del (5q) JAK2 V617F mutated cases and clinical presentation, morphological features, disease transformation or patient outcome [4, 5] , although a few cases presented with higher platelet and WBC count [3] . Lenalidomide was reported to be an effective treatment for the disease [6] .
We have recently studied a patient with del (5q) and JAK2 V617F mutation transformed to acute myeloid leukaemia (AML) with complex karyotype and increased JAK2 V617F mutation load.
A 66-year-old female presented with moderate anaemia and high platelet count (haemoglobin 100 g/l, WBC 7.2 × 10 9 /l, platelets 800 × 10 9 /l). Neutrophils were 4.95 × 10 9 /l, eosinophils 0.21 × 10 9 /l, monocytes 0.14 × 10 9 /l and lymphocytes 1.9 × 10 9 /l. No blast cell was present in the peripheral blood. There was no spleno-or hepatomegaly. On marrow aspirate, only eight metaphases showing a normal karyotype (46,XX) could be analysed, due to the lack of growth of an adequate number of metaphases and the poor cellularity of the sample. FISH analysis was limited to the study of 5q and demonstrated 5q31 deletion in 12 % of the nuclei. Thus, additional aberrations could not be identified. BCR/ABL rearrangements (p210, p190) were absent, while JAK2 V617F mutation displayed an allele burden of 4.28 %. Bone marrow (BM) biopsy showed a 70 % cellularity, slight dyserythropoiesis, moderate myeloid hyperplasia and marked proliferation of the megakaryocytic lineage with some dysplasia. A few megakaryocytes were large with hyperlobulated nuclei; others were medium-sized, with round and/or hypolobulated nuclei. There were 3 % CD34-positive blasts and moderate reticulin fibrosis (WHO MF-2). (Fig. 1a c, e). A strong nuclear p53 immunostaining was detected in 2 % haematopoietic cells (Fig. 1d ). We proposed a diagnosis of MDS with del (5q) and JAK2 V617F mutation. The patient did not receive any therapy. No organomegaly nor leukoerythroblastosis was reported during the course of the disease. Twenty-seven months later, she was admitted to the hospital because of persistent fever, severe anaemia and neutropenia (Hb level 7.5 g/l, WBC 2.3 × 10 9 /l, neutrophils 0.75 × 10 9 /l, platelets 137 × 10 9 /l). There were 5 % blast cells in the peripheral blood.
Chromosome banding analysis showed the following: 46, XX [1] / 45,XX, −7, del(5)(q13q33), del(13)(q14q34) [7] / 45, idem, del(2)(p12) [2] . FISH analysis demonstrated −7, del(5)(q31), del(13)(q14) (80 %) without BCR/ABL, AML1/ETO, PML/RARA, inv(16), MLL(11q23) translocation and +8. Molecular analysis did not identify FLT3 (ITD, D835), NPM1 (exon 12) or MLL-PTD mutations. Real-time quantitative polymerase chain reaction (RQ-PCR) detected 4164 WT1 copies/10 4 ABL copies and 55.6 % JAK2 V617F mutation load. p53 sequencing analysis of exons 2-11 showed a c.742C>T, p.R248W mutation in exon 7, that is considered a missense deleterious mutation. BM biopsy demonstrated marked dyserythro-, dysgranuloand dysmegakaryopoiesis; diffuse reticulin fibrosis and excess (25 %) of CD34-, CD117-, CD33-and MPO-positive blasts. (Fig. 1f, g, h, i, l) . Strong nuclear p53 immunostaining was found in more than 20 % of haematopoietic cells, including some blasts (Fig. 1m) .
A diagnosis of AML with myelodysplasia-related changes was established. Induction therapy with fludarabine, cytarabine and idarubicin failed; reinduction therapy with clofarabine and cytarabine was then performed. However, the disease still persisted in a control BM biopsy performed 3 months later.
Contrary to previous reports [4, 5] , our case of del (5q) with JAK2 V617F mutation transformed to AML. MDS with isolated del(5q) has a very long median survival (145 months) and a low rate of transformation (<10 %) to AML [1] . On the contrary, our case transformed to AML in 27 months only: it is possible that the simultaneous presence of del (5q), JAK2 V617F mutation and expression of p53 accelerated leukemic transformation. Indeed, a strong p53 immunostaining in >1 % of bone marrow progenitor cells is known to be significantly associated with higher acute myeloid leukaemia risk [7] .
The percentage of strongly p53-positive BM cells was 2 % at the time of the initial biopsy but more than 20 % at the time of the leukemic transformation and included some blasts. Sequencing confirmed a p53 mutation. Therefore, it is possible that p53 mutation contributed to the unfavourable course of this case.
Moreover, the increase of JAK2 V617F mutation load (10× of the initial value) can also explain the high number of large megakaryocytes with hyperlobulated or cloudy nuclei, typical of a MPN disease, that were appreciated in the BM biopsy performed at the time of the leukemic transformation.
WHO recommends to classify patients with isolated del (5q) and JAK2 V617F mutation in the MDS category rather than in the MDS/MPN category [1] .
However, the present case at diagnosis showed morphological features either of MDS and MPN. Furthermore, in the following transformation into AML, some morphological features of MPN were retained (large megakaryocytes with hyperlobulated or cloudy nuclei), together with myelodysplasia-related changes (marked dyserythro-, dysgranulo-and dysmegakaryopoiesis).
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